Cargando…

Propafenone Hepatotoxicity: Report of a New Case and Review of the Literature

Propafenone is a class Ic antiarrhythmic drug. It is a beta-adrenergic blocker that causes bradycardia and bronchospasm. It is metabolized primarily in the liver. Its bioavailability and plasma concentration differ among patients under long-term therapy. They are genetically determined by the hepati...

Descripción completa

Detalles Bibliográficos
Autores principales: Younan, Lara B., Barada, Kassem A., Faraj, Walid G., Tawil, Ayman N., Jabbour, Mark N., Khoury, Maurice Y., El-Majzoub, Nadim MW, Eloubeidi, Mohamad A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3793476/
https://www.ncbi.nlm.nih.gov/pubmed/24045598
http://dx.doi.org/10.4103/1319-3767.118137
Descripción
Sumario:Propafenone is a class Ic antiarrhythmic drug. It is a beta-adrenergic blocker that causes bradycardia and bronchospasm. It is metabolized primarily in the liver. Its bioavailability and plasma concentration differ among patients under long-term therapy. They are genetically determined by the hepatic cytochrome P-450 2D6. Hepatic toxicity is highly uncommon. To date, only eight patients were reported in the reviewed world literature. In this article, one new case will be reported emphasizing the importance of medication history taking in patients presenting with new-onset liver enzymes abnormalities.